
Juvenile Macular Degeneration Market
Description
Juvenile Macular Degeneration Market Report and Forecast 2024-2032
The juvenile macular degeneration market was valued at USD 0.9 billion in 2023, driven by the increasing demand for effective treatments that slow disease progression and preserve vision, alongside advancements in gene therapy and targeted drug treatments. The market is is projected to grow at a CAGR of 7.4% during the forecast period of 2024-2032, likely to attain a market value of USD 1.9 billion by 2032.
Juvenile Macular Degeneration Market Analysis
Juvenile macular degeneration (JMD) refers to a group of inherited eye conditions that affect the macula, the central part of the retina responsible for sharp vision. This condition primarily impacts children and teenagers, leading to progressive vision loss. JMD is a rare disorder, and research is focused on developing effective therapies, including drugs, dietary supplements, and advanced surgical techniques to manage and slow disease progression.
Market Drivers
Rising Incidence of Genetic Eye Disorders: The growing awareness of genetic eye disorders, including juvenile macular degeneration, is driving the demand for improved diagnostic and treatment options. Increased screening in children and teenagers has led to early identification of JMD, further propelling the market.
Advancements in Gene Therapy: Ongoing advancements in gene therapy are offering promising solutions for treating inherited forms of juvenile macular degeneration. These therapies aim to correct genetic defects at their source, offering long-term vision preservation, significantly driving market growth.
Development of Targeted Drug Therapies: The development of targeted drug therapies, including anti-vascular endothelial growth factor (VEGF) treatments, is improving patient outcomes. These drugs are helping to manage the disease more effectively by reducing abnormal blood vessel growth in the eyes, contributing to market expansion.
Increasing Government and Private Funding: Increased government and private sector funding for research and development into rare diseases, including juvenile macular degeneration, is helping accelerate the discovery of new treatments. This financial support is driving innovation and the introduction of novel therapies to the market.
Growing Focus on Early Detection: With a growing focus on early detection and intervention, diagnostic technologies for juvenile macular degeneration are becoming more sophisticated. Improved diagnostic tools allow for earlier treatment, which can slow disease progression and preserve vision, driving demand for advanced treatment options.
Challenges
Limited Awareness of JMD: One of the major challenges in the juvenile macular degeneration market is the limited awareness of the condition among the general public and healthcare professionals. Misdiagnosis or late diagnosis often delays treatment, affecting patient outcomes and market growth.
High Cost of Gene and Drug Therapies: The high cost of cutting-edge therapies, particularly gene therapies and targeted drug treatments, is a significant challenge in making treatments accessible to all patients. These costs limit the availability of effective treatments, particularly in low-income regions.
Lack of FDA-Approved Therapies for JMD: Currently, there are very few FDA-approved therapies specifically for juvenile macular degeneration. Most available treatments are adapted from age-related macular degeneration (AMD) therapies, which may not always be effective for younger patients, posing a challenge for the market.
Complexity of Inherited Disease Treatment: Treating inherited forms of juvenile macular degeneration presents significant challenges due to the complexity of genetic mutations involved. Developing effective treatments that address the underlying genetic causes requires extensive research, which slows the introduction of new therapies.
Limited Research into Non-Inherited Forms: While significant research is focused on inherited juvenile macular degeneration, there is a lack of substantial research into non-inherited or acquired forms. This limits the treatment options available for patients whose condition may not have a genetic origin, affecting overall market growth.
Future Opportunities
Expansion of Gene Therapy Applications: The successful application of gene therapies in other retinal diseases presents a significant opportunity for juvenile macular degeneration treatments. Continued research and innovation in gene editing techniques, such as CRISPR, could offer breakthroughs in correcting the genetic mutations that cause JMD.
Development of Novel Drug Delivery Systems: The development of novel drug delivery systems, such as sustained-release implants and intravitreal injections, offers opportunities to improve the efficacy of treatments for juvenile macular degeneration. These systems can provide more targeted and sustained therapeutic effects, reducing the need for frequent treatments.
Collaborations Between Research Institutes and Pharma Companies: Collaborations between pharmaceutical companies and research institutes present an opportunity to accelerate the development of novel treatments for juvenile macular degeneration. Joint research efforts can help bridge the gap between academic discoveries and market-ready therapies.
Increasing Adoption of Personalised Medicine: The increasing adoption of personalised medicine in ophthalmology offers opportunities for developing customised treatments for juvenile macular degeneration. Tailoring therapies to individual genetic profiles can improve treatment efficacy and reduce the likelihood of disease progression.
Juvenile Macular Degeneration Market Trends
The industry is evolving rapidly, driven by technological innovations and advancements in various practices. As continuous research uncovers new insights across sectors, several key trends are emerging, shaping the future direction of the market. These trends are expected to significantly influence the landscape, improving outcomes, enhancing precision, and expanding access to advanced solutions across products, therapies, and services.
Juvenile Macular Degeneration Market Segmentation
Market Breakup by Type
Dry Age-related Juvenile Macular Degeneration
Wet Age-related Juvenile Macular Degeneration
The juvenile macular degeneration market is segmented into dry and wet forms. Dry juvenile macular degeneration is more common and progresses slowly, often requiring dietary supplements and lifestyle changes for management. Wet juvenile macular degeneration, though less common, progresses rapidly and typically requires more intensive treatments like anti-VEGF therapies. Both segments are driving demand for targeted treatments.
Market Breakup by Disease Stage
Early-stage AMD
Intermediate AMD
Late-stage AMD
The market is divided by disease stage into early-stage, intermediate, and late-stage juvenile macular degeneration. Early-stage JMD is typically managed with lifestyle changes and dietary supplements, while intermediate and late-stage disease may require more aggressive treatments, including surgery and anti-VEGF therapies. The segmentation highlights the need for stage-specific treatments in managing the condition.
Market Breakup by Treatment Type
Drugs
Juvenile macular degeneration treatments are divided into drugs (such as anti-VEGF therapies and dietary supplements), devices (including glasses and contact lenses), and surgical interventions. Anti-VEGF drugs are commonly used in wet JMD, while dietary supplements and lifestyle changes are more typical in early-stage or dry forms of the disease. Surgical interventions are usually reserved for more severe cases.
Market Breakup by Route of Administration
Intravenous Route
Intravitreal Route
The market is segmented by the route of administration into intravenous and intravitreal routes. Intravitreal injections are commonly used for administering anti-VEGF drugs directly to the eye, ensuring targeted treatment. Intravenous routes are less common but are still used in specific clinical settings, particularly for drug infusions that require systemic administration.
Market Breakup by Age Group
Kids
Teenagers
The market is segmented by age group into kids and teenagers. Paediatric and adolescent patients with juvenile macular degeneration require specialised treatment plans, which are tailored to the progression of their condition and the impact on their daily activities. Treatments often focus on preserving vision and delaying disease progression as long as possible.
Market Breakup by Disease Type
Market Breakup by End User
Market Breakup by Distribution Channel
Market Breakup by Region
Juvenile Macular Degeneration Market Competitive Landscape
Key players in the juvenile macular degeneration market include Pfizer, Bayer AG, F-Hoffmann La Roche Ltd., Novartis AG, Panoptica Pharma, Bausch + Lomb, Regeneron Pharmaceuticals Inc., Ocugen Inc., REGENXBIO Inc., and Oxurion NV. These companies are focused on developing innovative treatments, including gene therapies, anti-VEGF drugs, and advanced diagnostic tools. Ongoing clinical trials, partnerships, and acquisitions are helping these firms strengthen their presence in the market.
Key Questions Answered in the Report
What are the key drivers of growth in the juvenile macular degeneration market?
How are advancements in gene therapy influencing treatment options for JMD?
What challenges do pharmaceutical companies face in developing therapies for juvenile macular degeneration?
Which market segments are seeing the most growth in the juvenile macular degeneration market?
How are anti-VEGF therapies shaping the treatment landscape for juvenile macular degeneration?
What role does early detection play in managing juvenile macular degeneration?
How are emerging markets influencing the growth of JMD treatments?
What opportunities exist for developing personalised treatments for juvenile macular degeneration?
How are collaborations between pharmaceutical companies and research institutions driving innovation in JMD therapies?
What trends are shaping the future of paediatric ophthalmology in managing JMD?
How are imaging technologies improving the diagnosis of juvenile macular degeneration?
What strategies are companies using to expand their presence in the juvenile macular degeneration market?
Key Benefits for Stakeholders
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the juvenile macular degeneration market from 2017-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in the juvenile macular degeneration market.
The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the juvenile macular degeneration industry and its attractiveness.
The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
The juvenile macular degeneration market was valued at USD 0.9 billion in 2023, driven by the increasing demand for effective treatments that slow disease progression and preserve vision, alongside advancements in gene therapy and targeted drug treatments. The market is is projected to grow at a CAGR of 7.4% during the forecast period of 2024-2032, likely to attain a market value of USD 1.9 billion by 2032.
Juvenile Macular Degeneration Market Analysis
Juvenile macular degeneration (JMD) refers to a group of inherited eye conditions that affect the macula, the central part of the retina responsible for sharp vision. This condition primarily impacts children and teenagers, leading to progressive vision loss. JMD is a rare disorder, and research is focused on developing effective therapies, including drugs, dietary supplements, and advanced surgical techniques to manage and slow disease progression.
Market Drivers
Rising Incidence of Genetic Eye Disorders: The growing awareness of genetic eye disorders, including juvenile macular degeneration, is driving the demand for improved diagnostic and treatment options. Increased screening in children and teenagers has led to early identification of JMD, further propelling the market.
Advancements in Gene Therapy: Ongoing advancements in gene therapy are offering promising solutions for treating inherited forms of juvenile macular degeneration. These therapies aim to correct genetic defects at their source, offering long-term vision preservation, significantly driving market growth.
Development of Targeted Drug Therapies: The development of targeted drug therapies, including anti-vascular endothelial growth factor (VEGF) treatments, is improving patient outcomes. These drugs are helping to manage the disease more effectively by reducing abnormal blood vessel growth in the eyes, contributing to market expansion.
Increasing Government and Private Funding: Increased government and private sector funding for research and development into rare diseases, including juvenile macular degeneration, is helping accelerate the discovery of new treatments. This financial support is driving innovation and the introduction of novel therapies to the market.
Growing Focus on Early Detection: With a growing focus on early detection and intervention, diagnostic technologies for juvenile macular degeneration are becoming more sophisticated. Improved diagnostic tools allow for earlier treatment, which can slow disease progression and preserve vision, driving demand for advanced treatment options.
Challenges
Limited Awareness of JMD: One of the major challenges in the juvenile macular degeneration market is the limited awareness of the condition among the general public and healthcare professionals. Misdiagnosis or late diagnosis often delays treatment, affecting patient outcomes and market growth.
High Cost of Gene and Drug Therapies: The high cost of cutting-edge therapies, particularly gene therapies and targeted drug treatments, is a significant challenge in making treatments accessible to all patients. These costs limit the availability of effective treatments, particularly in low-income regions.
Lack of FDA-Approved Therapies for JMD: Currently, there are very few FDA-approved therapies specifically for juvenile macular degeneration. Most available treatments are adapted from age-related macular degeneration (AMD) therapies, which may not always be effective for younger patients, posing a challenge for the market.
Complexity of Inherited Disease Treatment: Treating inherited forms of juvenile macular degeneration presents significant challenges due to the complexity of genetic mutations involved. Developing effective treatments that address the underlying genetic causes requires extensive research, which slows the introduction of new therapies.
Limited Research into Non-Inherited Forms: While significant research is focused on inherited juvenile macular degeneration, there is a lack of substantial research into non-inherited or acquired forms. This limits the treatment options available for patients whose condition may not have a genetic origin, affecting overall market growth.
Future Opportunities
Expansion of Gene Therapy Applications: The successful application of gene therapies in other retinal diseases presents a significant opportunity for juvenile macular degeneration treatments. Continued research and innovation in gene editing techniques, such as CRISPR, could offer breakthroughs in correcting the genetic mutations that cause JMD.
Development of Novel Drug Delivery Systems: The development of novel drug delivery systems, such as sustained-release implants and intravitreal injections, offers opportunities to improve the efficacy of treatments for juvenile macular degeneration. These systems can provide more targeted and sustained therapeutic effects, reducing the need for frequent treatments.
Collaborations Between Research Institutes and Pharma Companies: Collaborations between pharmaceutical companies and research institutes present an opportunity to accelerate the development of novel treatments for juvenile macular degeneration. Joint research efforts can help bridge the gap between academic discoveries and market-ready therapies.
Increasing Adoption of Personalised Medicine: The increasing adoption of personalised medicine in ophthalmology offers opportunities for developing customised treatments for juvenile macular degeneration. Tailoring therapies to individual genetic profiles can improve treatment efficacy and reduce the likelihood of disease progression.
Juvenile Macular Degeneration Market Trends
The industry is evolving rapidly, driven by technological innovations and advancements in various practices. As continuous research uncovers new insights across sectors, several key trends are emerging, shaping the future direction of the market. These trends are expected to significantly influence the landscape, improving outcomes, enhancing precision, and expanding access to advanced solutions across products, therapies, and services.
- Rising Popularity of Anti-VEGF Therapies
- Increased Research into Gene Therapy
- Growing Use of Diagnostic Imaging Technologies
- Focus on Paediatric Ophthalmology
- Adoption of Minimally Invasive Surgical Techniques
- Increased Funding for Rare Disease Research
Juvenile Macular Degeneration Market Segmentation
Market Breakup by Type
Dry Age-related Juvenile Macular Degeneration
Wet Age-related Juvenile Macular Degeneration
The juvenile macular degeneration market is segmented into dry and wet forms. Dry juvenile macular degeneration is more common and progresses slowly, often requiring dietary supplements and lifestyle changes for management. Wet juvenile macular degeneration, though less common, progresses rapidly and typically requires more intensive treatments like anti-VEGF therapies. Both segments are driving demand for targeted treatments.
Market Breakup by Disease Stage
Early-stage AMD
Intermediate AMD
Late-stage AMD
The market is divided by disease stage into early-stage, intermediate, and late-stage juvenile macular degeneration. Early-stage JMD is typically managed with lifestyle changes and dietary supplements, while intermediate and late-stage disease may require more aggressive treatments, including surgery and anti-VEGF therapies. The segmentation highlights the need for stage-specific treatments in managing the condition.
Market Breakup by Treatment Type
Drugs
- Anti-vascular Endothelial Growth Factor
- Dietary Supplements
- Others
- Glasses
- Contact Lenses
- Others
Juvenile macular degeneration treatments are divided into drugs (such as anti-VEGF therapies and dietary supplements), devices (including glasses and contact lenses), and surgical interventions. Anti-VEGF drugs are commonly used in wet JMD, while dietary supplements and lifestyle changes are more typical in early-stage or dry forms of the disease. Surgical interventions are usually reserved for more severe cases.
Market Breakup by Route of Administration
Intravenous Route
Intravitreal Route
The market is segmented by the route of administration into intravenous and intravitreal routes. Intravitreal injections are commonly used for administering anti-VEGF drugs directly to the eye, ensuring targeted treatment. Intravenous routes are less common but are still used in specific clinical settings, particularly for drug infusions that require systemic administration.
Market Breakup by Age Group
Kids
Teenagers
The market is segmented by age group into kids and teenagers. Paediatric and adolescent patients with juvenile macular degeneration require specialised treatment plans, which are tailored to the progression of their condition and the impact on their daily activities. Treatments often focus on preserving vision and delaying disease progression as long as possible.
Market Breakup by Disease Type
- Inherited
- Acquired
Market Breakup by End User
- Hospitals and Clinics
- Ambulatory Surgical Centers
- Homecare Settings
- Others
Market Breakup by Distribution Channel
- Hospitals Pharmacies
- Independent Pharmacies
- Online Pharmacies
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Juvenile Macular Degeneration Market Competitive Landscape
Key players in the juvenile macular degeneration market include Pfizer, Bayer AG, F-Hoffmann La Roche Ltd., Novartis AG, Panoptica Pharma, Bausch + Lomb, Regeneron Pharmaceuticals Inc., Ocugen Inc., REGENXBIO Inc., and Oxurion NV. These companies are focused on developing innovative treatments, including gene therapies, anti-VEGF drugs, and advanced diagnostic tools. Ongoing clinical trials, partnerships, and acquisitions are helping these firms strengthen their presence in the market.
Key Questions Answered in the Report
What are the key drivers of growth in the juvenile macular degeneration market?
How are advancements in gene therapy influencing treatment options for JMD?
What challenges do pharmaceutical companies face in developing therapies for juvenile macular degeneration?
Which market segments are seeing the most growth in the juvenile macular degeneration market?
How are anti-VEGF therapies shaping the treatment landscape for juvenile macular degeneration?
What role does early detection play in managing juvenile macular degeneration?
How are emerging markets influencing the growth of JMD treatments?
What opportunities exist for developing personalised treatments for juvenile macular degeneration?
How are collaborations between pharmaceutical companies and research institutions driving innovation in JMD therapies?
What trends are shaping the future of paediatric ophthalmology in managing JMD?
How are imaging technologies improving the diagnosis of juvenile macular degeneration?
What strategies are companies using to expand their presence in the juvenile macular degeneration market?
Key Benefits for Stakeholders
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the juvenile macular degeneration market from 2017-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in the juvenile macular degeneration market.
The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the juvenile macular degeneration industry and its attractiveness.
The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
250 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Juvenile Macular Degeneration Market Overview – 8 Major Markets
- 3.1 Juvenile Macular Degeneration Market Historical Value (2018-2024)
- 3.2 Juvenile Macular Degeneration Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Juvenile Macular Degeneration Market Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Juvenile Macular Degeneration Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 United States
- 7.1.1.2 United Kingdom
- 7.1.1.3 Germany
- 7.1.1.4 France
- 7.1.1.5 Italy
- 7.1.1.6 Spain
- 7.1.1.7 Japan
- 7.1.1.8 India
- 7.1.2 Diagnosed Cases, by Country
- 7.1.2.1 United States
- 7.1.2.2 United Kingdom
- 7.1.2.3 Germany
- 7.1.2.4 France
- 7.1.2.5 Italy
- 7.1.2.6 Spain
- 7.1.2.7 Japan
- 7.1.2.8 India
- 7.1.3 Treatment Seeking Rate, by Country
- 7.1.3.1 United States
- 7.1.3.2 United Kingdom
- 7.1.3.3 Germany
- 7.1.3.4 France
- 7.1.3.5 Italy
- 7.1.3.6 Spain
- 7.1.3.7 Japan
- 7.1.3.8 India
- 8 Juvenile Macular Degeneration Market Landscape – 8 Major Markets
- 8.1 Juvenile Macular Degeneration Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Juvenile Macular Degeneration Market: Product Landscape
- 8.2.1 Analysis by Type
- 8.2.2 Analysis by Treatment Type
- 8.2.3 Analysis by Route of Administration
- 9 Juvenile Macular Degeneration Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Juvenile Macular Degeneration Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Juvenile Macular Degeneration Market Segmentation (2018-2034) - 8 Major Markets
- 12.1 Juvenile Macular Degeneration Market (2018-2034) by Type
- 12.1.1 Market Overview
- 12.1.2 Dry Age-related Juvenile Macular Degeneration
- 12.1.3 Wet Age-related Juvenile Macular Degeneration
- 12.2 Juvenile Macular Degeneration Market (2018-2034) by Disease Stage
- 12.2.1 Market Overview
- 12.2.2 Early-stage AMD
- 12.2.3 Intermediate AMD
- 12.2.4 Late-stage AMD
- 12.3 Juvenile Macular Degeneration Market (2018-2034) by Treatment Type
- 12.3.1 Market Overview
- 12.3.2 Drugs
- 12.3.2.1 Anti-vascular Endothelial Growth Factor
- 12.3.2.2 Dietary Supplements
- 12.3.2.3 Others
- 12.3.3 Devices
- 12.3.3.1 Glasses
- 12.3.3.2 Contact Lenses
- 12.3.3.3 Others
- 12.3.4 Surgery
- 12.4 Juvenile Macular Degeneration Market (2018-2034) by Route of Administration
- 12.4.1 Market Overview
- 12.4.2 Intravenous Route
- 12.4.3 Intravitreal Route
- 12.5 Juvenile Macular Degeneration Market (2018-2034) by Age Group
- 12.5.1 Market Overview
- 12.5.2 Kids
- 12.5.3 Teenagers
- 12.6 Juvenile Macular Degeneration Market (2018-2034) by Disease Type
- 12.6.1 Market Overview
- 12.6.2 Inherited
- 12.6.3 Acquired
- 12.7 Juvenile Macular Degeneration Market (2018-2034) by End User
- 12.7.1 Market Overview
- 12.7.2 Hospitals & Clinics
- 12.7.3 Ambulatory Surgical Centers
- 12.7.4 Homecare Settings
- 12.7.5 Others
- 12.8 Juvenile Macular Degeneration Market (2018-2034) by Distribution Channel
- 12.8.1 Market Overview
- 12.8.2 Hospitals Pharmacies
- 12.8.3 Independent Pharmacies
- 12.8.4 Online Pharmacies
- 12.8.5 Others
- 12.9 Juvenile Macular Degeneration Market (2018-2034) by Country
- 12.9.1 Market Overview
- 12.9.2 United States
- 12.9.3 United Kingdom
- 12.9.4 Germany
- 12.9.5 France
- 12.9.6 Italy
- 12.9.7 Spain
- 12.9.8 Japan
- 12.9.9 India
- 13 United States Juvenile Macular Degeneration Market (2018-2034)
- 13.1 United States Juvenile Macular Degeneration Market Historical Value (2018-2024)
- 13.2 United States Juvenile Macular Degeneration Market Forecast Value (2025-2034)
- 13.3 United States Juvenile Macular Degeneration Market (2018-2034) by Type
- 13.3.1 Market Overview
- 13.3.2 Dry Age-related Juvenile Macular Degeneration
- 13.3.3 Wet Age-related Juvenile Macular Degeneration
- 13.4 United States Juvenile Macular Degeneration Market (2018-2034) by Disease Stage
- 13.4.1 Market Overview
- 13.4.2 Early-stage AMD
- 13.4.3 Intermediate AMD
- 13.4.4 Late-stage AMD
- 13.5 United States Juvenile Macular Degeneration Market (2018-2034) by Treatment Type
- 13.5.1 Market Overview
- 13.5.2 Drugs
- 13.5.2.1 Anti-vascular Endothelial Growth Factor
- 13.5.2.2 Dietary Supplements
- 13.5.2.3 Others
- 13.5.3 Devices
- 13.5.3.1 Glasses
- 13.5.3.2 Contact Lenses
- 13.5.3.3 Others
- 13.5.4 Surgery
- 13.6 United States Juvenile Macular Degeneration Market (2018-2034) by Route of Administration
- 13.6.1 Market Overview
- 13.6.2 Intravenous Route
- 13.6.3 Intravitreal Route
- 13.7 United States Juvenile Macular Degeneration Market (2018-2034) by Age Group
- 13.7.1 Market Overview
- 13.7.2 Kids
- 13.7.3 Teenagers
- 13.8 United States Juvenile Macular Degeneration Market (2018-2034) by Disease Type
- 13.8.1 Market Overview
- 13.8.2 Inherited
- 13.8.3 Acquired
- 13.9 United States Juvenile Macular Degeneration Market (2018-2034) by End User
- 13.9.1 Market Overview
- 13.9.2 Hospitals & Clinics
- 13.9.3 Ambulatory Surgical Centers
- 13.9.4 Homecare Settings
- 13.9.5 Others
- 13.10 United States Juvenile Macular Degeneration Market (2018-2034) by Distribution Channel
- 13.10.1 Market Overview
- 13.10.2 Hospitals Pharmacies
- 13.10.3 Independent Pharmacies
- 13.10.4 Online Pharmacies
- 13.10.5 Others
- 14 United Kingdom Juvenile Macular Degeneration Market (2018-2034)
- 14.1 United Kingdom Juvenile Macular Degeneration Market Historical Value (2018-2024)
- 14.2 United Kingdom Juvenile Macular Degeneration Market Forecast Value (2025-2034)
- 14.3 United Kingdom Juvenile Macular Degeneration Market (2018-2034) by Type
- 14.3.1 Market Overview
- 14.3.2 Dry Age-related Juvenile Macular Degeneration
- 14.3.3 Wet Age-related Juvenile Macular Degeneration
- 14.4 United Kingdom Juvenile Macular Degeneration Market (2018-2034) by Disease Stage
- 14.4.1 Market Overview
- 14.4.2 Early-stage AMD
- 14.4.3 Intermediate AMD
- 14.4.4 Late-stage AMD
- 14.5 United Kingdom Juvenile Macular Degeneration Market (2018-2034) by Treatment Type
- 14.5.1 Market Overview
- 14.5.2 Drugs
- 14.5.2.1 Anti-vascular Endothelial Growth Factor
- 14.5.2.2 Dietary Supplements
- 14.5.2.3 Others
- 14.5.3 Devices
- 14.5.3.1 Glasses
- 14.5.3.2 Contact Lenses
- 14.5.3.3 Others
- 14.5.4 Surgery
- 14.6 United Kingdom Juvenile Macular Degeneration Market (2018-2034) by Route of Administration
- 14.6.1 Market Overview
- 14.6.2 Intravenous Route
- 14.6.3 Intravitreal Route
- 14.7 United Kingdom Juvenile Macular Degeneration Market (2018-2034) by Age Group
- 14.7.1 Market Overview
- 14.7.2 Kids
- 14.7.3 Teenagers
- 14.8 United Kingdom Juvenile Macular Degeneration Market (2018-2034) by Disease Type
- 14.8.1 Market Overview
- 14.8.2 Inherited
- 14.8.3 Acquired
- 14.9 United Kingdom Juvenile Macular Degeneration Market (2018-2034) by End User
- 14.9.1 Market Overview
- 14.9.2 Hospitals & Clinics
- 14.9.3 Ambulatory Surgical Centers
- 14.9.4 Homecare Settings
- 14.9.5 Others
- 14.10 United Kingdom Juvenile Macular Degeneration Market (2018-2034) by Distribution Channel
- 14.10.1 Market Overview
- 14.10.2 Hospitals Pharmacies
- 14.10.3 Independent Pharmacies
- 14.10.4 Online Pharmacies
- 14.10.5 Others
- 15 France Juvenile Macular Degeneration Market (2018-2034)
- 15.1 France Juvenile Macular Degeneration Market Historical Value (2018-2024)
- 15.2 France Juvenile Macular Degeneration Market Forecast Value (2025-2034)
- 15.3 France Juvenile Macular Degeneration Market (2018-2034) by Type
- 15.3.1 Market Overview
- 15.3.2 Dry Age-related Juvenile Macular Degeneration
- 15.3.3 Wet Age-related Juvenile Macular Degeneration
- 15.4 France Juvenile Macular Degeneration Market (2018-2034) by Disease Stage
- 15.4.1 Market Overview
- 15.4.2 Early-stage AMD
- 15.4.3 Intermediate AMD
- 15.4.4 Late-stage AMD
- 15.5 France Juvenile Macular Degeneration Market (2018-2034) by Treatment Type
- 15.5.1 Market Overview
- 15.5.2 Drugs
- 15.5.2.1 Anti-vascular Endothelial Growth Factor
- 15.5.2.2 Dietary Supplements
- 15.5.2.3 Others
- 15.5.3 Devices
- 15.5.3.1 Glasses
- 15.5.3.2 Contact Lenses
- 15.5.3.3 Others
- 15.5.4 Surgery
- 15.6 France Juvenile Macular Degeneration Market (2018-2034) by Route of Administration
- 15.6.1 Market Overview
- 15.6.2 Intravenous Route
- 15.6.3 Intravitreal Route
- 15.7 France Juvenile Macular Degeneration Market (2018-2034) by Age Group
- 15.7.1 Market Overview
- 15.7.2 Kids
- 15.7.3 Teenagers
- 15.8 France Juvenile Macular Degeneration Market (2018-2034) by Disease Type
- 15.8.1 Market Overview
- 15.8.2 Inherited
- 15.8.3 Acquired
- 15.9 France Juvenile Macular Degeneration Market (2018-2034) by End User
- 15.9.1 Market Overview
- 15.9.2 Hospitals & Clinics
- 15.9.3 Ambulatory Surgical Centers
- 15.9.4 Homecare Settings
- 15.9.5 Others
- 15.10 France Juvenile Macular Degeneration Market (2018-2034) by Distribution Channel
- 15.10.1 Market Overview
- 15.10.2 Hospitals Pharmacies
- 15.10.3 Independent Pharmacies
- 15.10.4 Online Pharmacies
- 15.10.5 Others
- 16 Italy Juvenile Macular Degeneration Market (2018-2034)
- 16.1 Italy Juvenile Macular Degeneration Market Historical Value (2018-2024)
- 16.2 Italy Juvenile Macular Degeneration Market Forecast Value (2025-2034)
- 16.3 Italy Juvenile Macular Degeneration Market (2018-2034) by Type
- 16.3.1 Market Overview
- 16.3.2 Dry Age-related Juvenile Macular Degeneration
- 16.3.3 Wet Age-related Juvenile Macular Degeneration
- 16.4 Italy Juvenile Macular Degeneration Market (2018-2034) by Disease Stage
- 16.4.1 Market Overview
- 16.4.2 Early-stage AMD
- 16.4.3 Intermediate AMD
- 16.4.4 Late-stage AMD
- 16.5 Italy Juvenile Macular Degeneration Market (2018-2034) by Treatment Type
- 16.5.1 Market Overview
- 16.5.2 Drugs
- 16.5.2.1 Anti-vascular Endothelial Growth Factor
- 16.5.2.2 Dietary Supplements
- 16.5.2.3 Others
- 16.5.3 Devices
- 16.5.3.1 Glasses
- 16.5.3.2 Contact Lenses
- 16.5.3.3 Others
- 16.5.4 Surgery
- 16.6 Italy Juvenile Macular Degeneration Market (2018-2034) by Route of Administration
- 16.6.1 Market Overview
- 16.6.2 Intravenous Route
- 16.6.3 Intravitreal Route
- 16.7 Italy Juvenile Macular Degeneration Market (2018-2034) by Age Group
- 16.7.1 Market Overview
- 16.7.2 Kids
- 16.7.3 Teenagers
- 16.8 Italy Juvenile Macular Degeneration Market (2018-2034) by Disease Type
- 16.8.1 Market Overview
- 16.8.2 Inherited
- 16.8.3 Acquired
- 16.9 Italy Juvenile Macular Degeneration Market (2018-2034) by End User
- 16.9.1 Market Overview
- 16.9.2 Hospitals & Clinics
- 16.9.3 Ambulatory Surgical Centers
- 16.9.4 Homecare Settings
- 16.9.5 Others
- 16.10 Italy Juvenile Macular Degeneration Market (2018-2034) by Distribution Channel
- 16.10.1 Market Overview
- 16.10.2 Hospitals Pharmacies
- 16.10.3 Independent Pharmacies
- 16.10.4 Online Pharmacies
- 16.10.5 Others
- 17 Spain Juvenile Macular Degeneration Market (2018-2034)
- 17.1 Spain Juvenile Macular Degeneration Market Historical Value (2018-2024)
- 17.2 Spain Juvenile Macular Degeneration Market Forecast Value (2025-2034)
- 17.3 Spain Juvenile Macular Degeneration Market (2018-2034) by Type
- 17.3.1 Market Overview
- 17.3.2 Dry Age-related Juvenile Macular Degeneration
- 17.3.3 Wet Age-related Juvenile Macular Degeneration
- 17.4 Spain Juvenile Macular Degeneration Market (2018-2034) by Disease Stage
- 17.4.1 Market Overview
- 17.4.2 Early-stage AMD
- 17.4.3 Intermediate AMD
- 17.4.4 Late-stage AMD
- 17.5 Spain Juvenile Macular Degeneration Market (2018-2034) by Treatment Type
- 17.5.1 Market Overview
- 17.5.2 Drugs
- 17.5.2.1 Anti-vascular Endothelial Growth Factor
- 17.5.2.2 Dietary Supplements
- 17.5.2.3 Others
- 17.5.3 Devices
- 17.5.3.1 Glasses
- 17.5.3.2 Contact Lenses
- 17.5.3.3 Others
- 17.5.4 Surgery
- 17.6 Spain Juvenile Macular Degeneration Market (2018-2034) by Route of Administration
- 17.6.1 Market Overview
- 17.6.2 Intravenous Route
- 17.6.3 Intravitreal Route
- 17.7 Spain Juvenile Macular Degeneration Market (2018-2034) by Age Group
- 17.7.1 Market Overview
- 17.7.2 Kids
- 17.7.3 Teenagers
- 17.8 Spain Juvenile Macular Degeneration Market (2018-2034) by Disease Type
- 17.8.1 Market Overview
- 17.8.2 Inherited
- 17.8.3 Acquired
- 17.9 Spain Juvenile Macular Degeneration Market (2018-2034) by End User
- 17.9.1 Market Overview
- 17.9.2 Hospitals & Clinics
- 17.9.3 Ambulatory Surgical Centers
- 17.9.4 Homecare Settings
- 17.9.5 Others
- 17.10 Spain Juvenile Macular Degeneration Market (2018-2034) by Distribution Channel
- 17.10.1 Market Overview
- 17.10.2 Hospitals Pharmacies
- 17.10.3 Independent Pharmacies
- 17.10.4 Online Pharmacies
- 17.10.5 Others
- 18 Japan Juvenile Macular Degeneration Market
- 18.1 Japan Juvenile Macular Degeneration Market Historical Value (2018-2024)
- 18.2 Japan Juvenile Macular Degeneration Market Forecast Value (2025-2034)
- 18.3 Japan Juvenile Macular Degeneration Market (2018-2034) by Type
- 18.3.1 Market Overview
- 18.3.2 Dry Age-related Juvenile Macular Degeneration
- 18.3.3 Wet Age-related Juvenile Macular Degeneration
- 18.4 Japan Juvenile Macular Degeneration Market (2018-2034) by Disease Stage
- 18.4.1 Market Overview
- 18.4.2 Early-stage AMD
- 18.4.3 Intermediate AMD
- 18.4.4 Late-stage AMD
- 18.5 Japan Juvenile Macular Degeneration Market (2018-2034) by Treatment Type
- 18.5.1 Market Overview
- 18.5.2 Drugs
- 18.5.2.1 Anti-vascular Endothelial Growth Factor
- 18.5.2.2 Dietary Supplements
- 18.5.2.3 Others
- 18.5.3 Devices
- 18.5.3.1 Glasses
- 18.5.3.2 Contact Lenses
- 18.5.3.3 Others
- 18.5.4 Surgery
- 18.6 Japan Juvenile Macular Degeneration Market (2018-2034) by Route of Administration
- 18.6.1 Market Overview
- 18.6.2 Intravenous Route
- 18.6.3 Intravitreal Route
- 18.7 Japan Juvenile Macular Degeneration Market (2018-2034) by Age Group
- 18.7.1 Market Overview
- 18.7.2 Kids
- 18.7.3 Teenagers
- 18.8 Japan Juvenile Macular Degeneration Market (2018-2034) by Disease Type
- 18.8.1 Market Overview
- 18.8.2 Inherited
- 18.8.3 Acquired
- 18.9 Japan Juvenile Macular Degeneration Market (2018-2034) by End User
- 18.9.1 Market Overview
- 18.9.2 Hospitals & Clinics
- 18.9.3 Ambulatory Surgical Centers
- 18.9.4 Homecare Settings
- 18.9.5 Others
- 18.10 Japan Juvenile Macular Degeneration Market (2018-2034) by Distribution Channel
- 18.10.1 Market Overview
- 18.10.2 Hospitals Pharmacies
- 18.10.3 Independent Pharmacies
- 18.10.4 Online Pharmacies
- 18.10.5 Others
- 19 India Juvenile Macular Degeneration Market
- 19.1 India Juvenile Macular Degeneration Market (2018-2034) Historical Value (2018-2024)
- 19.2 India Juvenile Macular Degeneration Market (2018-2034) Forecast Value (2025-2034)
- 19.3 India Juvenile Macular Degeneration Market (2018-2034) by Type
- 19.3.1 Market Overview
- 19.3.2 Dry Age-related Juvenile Macular Degeneration
- 19.3.3 Wet Age-related Juvenile Macular Degeneration
- 19.4 India Juvenile Macular Degeneration Market (2018-2034) by Disease Stage
- 19.4.1 Market Overview
- 19.4.2 Early-stage AMD
- 19.4.3 Intermediate AMD
- 19.4.4 Late-stage AMD
- 19.5 India Juvenile Macular Degeneration Market (2018-2034) by Treatment Type
- 19.5.1 Market Overview
- 19.5.2 Drugs
- 19.5.2.1 Anti-vascular Endothelial Growth Factor
- 19.5.2.2 Dietary Supplements
- 19.5.2.3 Others
- 19.5.3 Devices
- 19.5.3.1 Glasses
- 19.5.3.2 Contact Lenses
- 19.5.3.3 Others
- 19.5.4 Surgery
- 19.6 India Juvenile Macular Degeneration Market (2018-2034) by Route of Administration
- 19.6.1 Market Overview
- 19.6.2 Intravenous Route
- 19.6.3 Intravitreal Route
- 19.7 India Juvenile Macular Degeneration Market (2018-2034) by Age Group
- 19.7.1 Market Overview
- 19.7.2 Kids
- 19.7.3 Teenagers
- 19.8 India Juvenile Macular Degeneration Market (2018-2034) by Disease Type
- 19.8.1 Market Overview
- 19.8.2 Inherited
- 19.8.3 Acquired
- 19.9 India Juvenile Macular Degeneration Market (2018-2034) by End User
- 19.9.1 Market Overview
- 19.9.2 Hospitals & Clinics
- 19.9.3 Ambulatory Surgical Centers
- 19.9.4 Homecare Settings
- 19.9.5 Others
- 19.10 India Juvenile Macular Degeneration Market (2018-2034) by Distribution Channel
- 19.10.1 Market Overview
- 19.10.2 Hospitals Pharmacies
- 19.10.3 Independent Pharmacies
- 19.10.4 Online Pharmacies
- 19.10.5 Others
- 20 Regulatory Framework
- 20.1 Regulatory Overview
- 20.2 US FDA
- 20.3 EU EMA
- 20.4 Japan PMDA
- 20.5 India CDSCO
- 20.6 Others
- 21 Patent Analysis
- 21.1 Analysis by Type of Patent
- 21.2 Analysis by Publication Year
- 21.3 Analysis by Issuing Authority
- 21.4 Analysis by Patent Age
- 21.5 Analysis by CPC Analysis
- 21.6 Analysis by Patent Valuation
- 21.7 Analysis by Key Players
- 22 Clinical Trials and Pipeline Analysis
- 22.1 Analysis by Trial Registration Year
- 22.2 Analysis by Trial Status
- 22.3 Analysis by Trial Phase
- 22.4 Analysis by Therapeutic Area
- 22.5 Analysis by Geography
- 22.6 Type Pipeline Assessment
- 23 Grants Analysis
- 23.1 Analysis by Year
- 23.2 Analysis by Amount Awarded
- 23.3 Analysis by Issuing Authority
- 23.4 Analysis by Grant Application
- 23.5 Analysis by Funding Institute
- 23.6 Analysis by NIH Departments
- 23.7 Analysis by Recipient Organization
- 24 Funding and Investment Analysis
- 24.1 Analysis by Funding Instances
- 24.2 Analysis by Type of Funding
- 24.3 Analysis by Funding Amount
- 24.4 Analysis by Leading Players
- 24.5 Analysis by Leading Investors
- 24.6 Analysis by Geography
- 25 Strategic Initiatives
- 25.1 Analysis by Partnership Instances
- 25.2 Analysis by Type of Partnership
- 25.3 Analysis by Leading Players
- 25.4 Analysis by Geography
- 26 Supplier Landscape
- 26.1 Market Share by Top 5 Companies
- 26.2 Pfizer, Inc.
- 26.2.1 Financial Analysis
- 26.2.2 Product Portfolio
- 26.2.3 Demographic Reach and Achievements
- 26.2.4 Companies News and Developments
- 26.2.5 Certifications
- 26.3 Bayer AG
- 26.3.1 Financial Analysis
- 26.3.2 Product Portfolio
- 26.3.3 Demographic Reach and Achievements
- 26.3.4 Companies News and Developments
- 26.3.5 Certifications
- 26.4 F-Hoffmann La Roche Ltd.
- 26.4.1 Financial Analysis
- 26.4.2 Product Portfolio
- 26.4.3 Demographic Reach and Achievements
- 26.4.4 Companies News and Developments
- 26.4.5 Certifications
- 26.5 Novartis AG
- 26.5.1 Financial Analysis
- 26.5.2 Product Portfolio
- 26.5.3 Demographic Reach and Achievements
- 26.5.4 Companies News and Developments
- 26.5.5 Certifications
- 26.6 Panoptica Pharma
- 26.6.1 Financial Analysis
- 26.6.2 Product Portfolio
- 26.6.3 Demographic Reach and Achievements
- 26.6.4 Companies News and Developments
- 26.6.5 Certifications
- 26.7 Bausch + Lomb
- 26.7.1 Financial Analysis
- 26.7.2 Product Portfolio
- 26.7.3 Demographic Reach and Achievements
- 26.7.4 Companies News and Developments
- 26.7.5 Certifications
- 26.8 Regeneron Pharmaceuticals Inc.
- 26.8.1 Financial Analysis
- 26.8.2 Product Portfolio
- 26.8.3 Demographic Reach and Achievements
- 26.8.4 Companies News and Developments
- 26.8.5 Certifications
- 26.9 Ocugen Inc.
- 26.9.1 Financial Analysis
- 26.9.2 Product Portfolio
- 26.9.3 Demographic Reach and Achievements
- 26.9.4 Companies News and Developments
- 26.9.5 Certifications
- 26.10 Oxurion NV
- 26.10.1 Financial Analysis
- 26.10.2 Product Portfolio
- 26.10.3 Demographic Reach and Achievements
- 26.10.4 Companies News and Developments
- 26.10.5 Certifications
- 26.11 REGENXBIO Inc.
- 26.11.1 Financial Analysis
- 26.11.2 Product Portfolio
- 26.11.3 Demographic Reach and Achievements
- 26.11.4 Companies News and Developments
- 26.11.5 Certifications
- 27 Key Opinion Leaders (KOL) Insights (Additional Insight)
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
- **The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.